Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
CELLULAR IMMUNOLOGY, ANTIBODIES, AND MEDIATORS OF IMMUNITY

Association of Selective HLA Class II Susceptibility-Conferring and Protective Haplotypes with Type 2 Diabetes in Patients from Bahrain and Lebanon

Wassim Y. Almawi, Saria F. Wakim-Ghorayeb, Mona R. Arekat, Pierre Najm, Sose H. Keleshian, Nasreen Al-Sayed, Bruno Blanchon, Hanady R. Samaha, Noha Irani-Hakime
Wassim Y. Almawi
1College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wyalmawi@yahoo.co.uk
Saria F. Wakim-Ghorayeb
2St. Georges University Hospital, Beirut, Lebanon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mona R. Arekat
3Joslin Diabetes Center-Bahrain, Manama, Bahrain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Najm
2St. Georges University Hospital, Beirut, Lebanon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sose H. Keleshian
4Haigazian University, Beirut, Lebanon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nasreen Al-Sayed
3Joslin Diabetes Center-Bahrain, Manama, Bahrain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Blanchon
3Joslin Diabetes Center-Bahrain, Manama, Bahrain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanady R. Samaha
2St. Georges University Hospital, Beirut, Lebanon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noha Irani-Hakime
2St. Georges University Hospital, Beirut, Lebanon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/CVI.00206-06
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The association of HLA class II with type 2 diabetes (T2DM) was investigated in Bahraini and Lebanese subjects. DRB1*070101 (Lebanese and Bahraini) and DQB1*0201 (Lebanese) were susceptibility-conferring alleles, and unique susceptibility-conferring/protective haplotypes were found in both patient groups. Regression analysis confirmed that DRB1*070101-DQB1*0201 (Bahraini) and DRB1*110101-DQB1*0201 (Lebanese) were susceptibility-conferring haplotypes.

Type 2 (non-insulin-dependent) diabetes mellitus (T2DM) is the most common diabetes form (19), and susceptibility to it is determined by environmental and genetic factors (9, 19), the latter being complex and poorly defined (5, 19). While the association of HLA class II genes in type 1 diabetes pathogenesis was reported for several ethnicities (1, 14), studies on HLA class II association with T2DM provided inconsistent results, since an association (16), no association (7), or a weak link between HLA class II and T2DM has been reported. A number of studies focused on the association of HLA with T2DM morbidity and mortality (17), highlighted by increased frequency of HLA-DR3 and -DR4 in islet cell autoantibody (ICA)-positive patients refractory to oral anti-diabetic drugs as reported by some (11) but not others (20), and association of HLA-DRB1*1502 with T2DM in anti-glutamic acid decarboxylase (GAD)-positive patients (10).

We previously reported on the distribution of HLA class II alleles and haplotypes among T2DM patients in the Bahraini population (16), an Arab Peninsula population with a high prevalence (24% of the adult population) of T2DM (2). In view of the heterogeneity of Arabs with distinct ethnic backgrounds and racial origins (3), this study addresses the association of HLA-DRB1 and HLA-DQB1 haplotypes with T2DM in Bahraini and Lebanese Arabs.

T2DM patients comprised 115 Lebanese (59 males and 56 females; mean age, 55.2 ± 13.5 years) and 110 Bahraini (59 males and 51 females; mean age, 52.3 ± 9.6 years) unrelated patients. Exclusion criteria included other types of diabetes, autoimmune diseases, and positive anti-GAD, anti-protein tyrosine phosphatase-related protein (IA-2), or ICA autoantibody responses. Family history of diabetes (80/110 Bahraini patients and 77/115 Lebanese patients) or body mass index did not influence selection of subjects. The control group included 121 Lebanese (57 males and 64 females; mean age, 54.5 ± 13.8 years) and 154 Bahraini (79 males and 75 females; mean age, 52.9 ± 9.0 years) subjects with normal fasting/random glucose levels and no known personal or family history of diabetes. Demographic details, which included duration, first-degree family history, complications, and treatment for diabetes, were recorded. The Arabian Gulf University Ethics Committee approved the study (which was done according to Helsinki guidelines), and informed consent was obtained from all participants.

Total genomic DNA was extracted from EDTA-anticoagulated venous blood by the phenol-chloroform method. HLA-DRB1 and HLA-DQB1 gene alleles were analyzed using the PCR sequence-specific priming (SSP) technique, using an SSP2L HLA class II genotyping kit according to the manufacturer's specifications (One Lambda, Thousand Oaks, CA). Allele frequencies were determined by the gene counting method, and haplotype frequencies were determined by the maximum likelihood method, using the Arlequin (version 2.000) population analysis software. P values were corrected for the number of alleles tested (Pc) using Bonferroni's inequality method; significance was determined at a P value of <0.05.

Significant DRB1 and DQB1 allelic differences were seen between Lebanese and Bahraini T2DM patients and controls. When Bonferroni's correction was applied, DRB1*070101 was significantly more common in both patient groups. While DQB1*0201 was significantly more common among Lebanese patients, none of the DQB1 loci were found to be significantly different between Bahraini patients and controls (Table 1). DRB1-DQB1 haplotype analysis showed that the frequency of DRB1*110101-DQB1*0201 was higher, while the frequencies of DRB1*040101-DQB1*050101, DRB1*110101-DQB1*030101, DRB1*130101-DQB1*060101, and DRB1*140101-DQB1*050101 were lower in Lebanese patients than in controls (Table 2). The frequencies of DRB1*040101-DQB1*0302 and DRB1*070101-DQB1*0201 were higher, while the frequency of DRB1*110101-DQB1*0201 was lower in Bahraini patients than in controls (Table 2). Logistic regression analysis demonstrated, after controlling for confounding variables, that DRB1*070101-DQB1*0201 and DRB1*110101-DQB1*0201 served a dominant role among Bahraini and Lebanese subjects, respectively (Table 3). Other haplotypes were rejected according to the model employed.

Unique susceptibility-conferring and protective HLA class II haplotypes were seen among Bahraini and Lebanese T2DM patients, with DR7- and DR4-containing (Bahraini) as well as DR11-containing (Lebanese) haplotypes being positively associated with T2DM. Whereas DR4-containing haplotypes conferred susceptibility among Bahraini patients, they were protective among their Lebanese counterparts. DRB1*110101-DQB1*0201 served a susceptibility-conferring role among Lebanese patients but was largely protective among Bahraini patients. The susceptibility conferred by DRB1*040101-DQB1*0302 and DRB1*070101-DQB1*0201 haplotypes among Bahraini subjects confirmed our previous finding (16), with key differences between the two studies, as DRB1*160101-DQB1*050101 was reported earlier to be protective and DRB1*150101-DQB1*060101 and DRB1*070101-DQB1*050101 were reported to confer susceptibility (16). This was largely due to the larger sample analyzed here (110 patients versus 89 patients).

DRB1*040101-DQB1*0302 conferred disease susceptibility in Bahraini patients, in agreement with previous studies on Caucasian (6) and non-Caucasian (8, 12) patients, but in disagreement with others which suggested that DR4 was protective (17). This may be due to ethnic background, patient selection, and sample size. In contrast to the case for Bahrainis, DRB1*040101-DQB1*0302 was neutral among Lebanese patients due to the high prevalence of DRB1*04 among healthy Lebanese (3) and other Mediterranean populations (15). DRB1*110101 was positively or negatively associated with T2DM when present with DQB1*0201 or DQB1*030101, respectively, suggesting that DRB1*110101 did not influence the disease susceptibility, which apparently resided in the DQB1 allele it associated with (18).

While DRB1*070101 was the susceptibility allele in both Lebanese and Bahraini patients, DQB1*0201 was present at higher frequency among Lebanese patients than among Bahraini patients due to the high prevalence of DQB1*0201 among healthy Bahrainis (3). Regression analysis confirmed that DRB1*070101-DQB1*0201 (Bahrain) or DRB1*110101-DQB1*0201 (Lebanon) was a risk factor for T2DM, indicating that HLA class II genotype influenced T2DM pathogenesis in these communities. While the association of specific HLA genotypes with T2DM reportedly disappeared after controlling for GAD or ICA levels (13), this does not appear to be the case here, as all patients were GAD and ICA negative.

While the mechanisms underlying these associations remain to be seen, it is possible that the association of DRB1-DQB1 haplotypes with T2DM and its complications may reside in differential affinity to antigenic fragments presented by each haplotype (4). Susceptibility-conferring haplotypes may bind to and present specific antigens, thereby precipitating hypoglycemia, while “protective” haplotypes may have reduced or no affinity for such antigens. A larger study which addresses class II genotype distribution among T2DM from other communities with a high T2DM prevalence, together with functional association with T2DM complications and response to therapy, are needed to confirm the association of HLA class II with T2DM.

View this table:
  • View inline
  • View popup
TABLE 1.

HLA-DRB1* allele distribution among T2DM patients and controlsa

View this table:
  • View inline
  • View popup
TABLE 2.

DRB1*-DQB1* haplotype distribution

View this table:
  • View inline
  • View popup
TABLE 3.

Multinomial regression analysisa

FOOTNOTES

    • Received 3 June 2006.
    • Returned for modification 17 July 2006.
    • Accepted 12 September 2006.
  • Copyright © 2006 American Society for Microbiology

REFERENCES

  1. 1.↵
    Al-Jenaidi, F. A., S. F. Wakim-Ghorayeb, A. Al-Abbasi, M. R. Arekat, N. Irani-Hakime, P. Najm, K. Al-Ola, A. A. Motala, and W. Y. Almawi. 2005. Contribution of selective HLA-DRB1/DQB1 alleles and haplotypes to the genetic susceptibility of type 1 diabetes among Lebanese and Bahraini Arabs. J. Clin. Endocrinol. Metab.90:5104-5109.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Al-Mahroos, F., and P. M. McKeigue. 1998. High prevalence of diabetes in Bahrainis. Associations with ethnicity and raised plasma cholesterol. Diabetes Care21:936-942.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Almawi, W. Y., M. Busson, H. Tamim, E. M. Al-Harbi, R. R. Finan, S. F. Wakim-Ghorayeb, and A. A. Motala. 2004. HLA class II profile and distribution of HLA-DRB1 and HLA-DQB1 alleles and haplotypes among Lebanese and Bahraini Arabs. Clin. Diagn. Lab. Immunol.11:770-774.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Bach, J. M., H. Otto, G. T. Nepom, G. Jung, H. Cohen, J. Timsit, C. Boitard, and P. M. van Endert. 1997. High affinity presentation of an autoantigenic peptide in type I diabetes by an HLA class II protein encoded in a haplotype protecting from disease. J. Autoimmun.10:375-386.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Barroso, I. 2005. Genetics of type 2 diabetes. Diabet. Med.22:517-535.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Bottazzo, G. F., E. Bosi, C. A. Cull, E. Bonifacio, M. Locatelli, P. Zimmet, I. R. Mackay, and R. R. Holman. 2005. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia48:703-708.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    Cerna, M., P. Novota, K. Kolostova, P. Cejkova, E. Zdarsky, D. Novakova, P. Kucera, J. Novak, and M. Andel. 2003. HLA in Czech adult patients with autoimmune diabetes mellitus: comparison with Czech children with type 1 diabetes and patients with type 2 diabetes. Eur. J. Immunogenet.30:401-407.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Dyck, R., C. Bohm, and H. Klomp. 2003. Increased frequency of HLA A2/DR4 and A2/DR8 haplotypes in young Saskatchewan aboriginal people with diabetic end-stage renal disease. Am. J. Nephrol.23:178-185.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Egede, L. E., and S. Dagogo-Jack. 2005. Epidemiology of type 2 diabetes: focus on ethnic minorities. Med. Clin. N. Am.89:949-975.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    Fukui, M., K. Nakano, N. Nakamura, E. Maruya, H. Saji, H. Obayashi, K. Ohta, M. Ohta, H. Mori, S. Kajiyama, S. Wada, Y. Kida, K. Kosaka, M. Deguchi, H. Shigeta, Y. Kitagawa, and M. Kondo. 1998. HLA-DRB1 alleles contribute to determining the prognosis of Japanese diabetes mellitus positive for antibodies to glutamate decarboxylase. J. Clin. Immunol.18:89-92.
    OpenUrlCrossRefPubMed
  11. 11.↵
    Groop, L., A. Miettinen, P. H. Groop, S. Meri, S. Koskimies, and G. F. Bottazzo. 1988. Organ-specific autoimmunity and HLA-DR antigens as markers for beta-cell destruction in patients with type II diabetes. Diabetes37:99-103.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Hamaguchi, K., A. Kimura, Y. Kusuda, T. Yamashita, M. Yasunami, M. Takahasi, N. Abe, and H. Yoshimatsu. 2004. Clinical and genetic characteristics of GAD-antibody positive patients initially diagnosed as having type 2 diabetes. Diabetes Res. Clin. Pract.66:163-171.
    OpenUrlCrossRefPubMed
  13. 13.↵
    Horton, V., I. Stratton, G. F. Bottazzo, M. Shattock, I. Mackay, P. Zimmet, S. Manley, R. Holman, R. Turner, et al. 1999. Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB genotypes (UKPDS 43). Diabetologia42:608-616.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Kawabata, Y., H. Ikegami, Y. Kawaguchi, T. Fujisawa, M. Shintani, M. Ono, M. Nishino, Y. Uchigata, I. Lee, and T. Ogihara. 2002. Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes to susceptibility to type 1 diabetes. Diabetes51:545-551.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Kwon, O. J., C. Brautbar, N. Weintrob, E. Sprecher, C. Saphirman, K. Bloch, O. Pinhas-Hamiel, S. Assah, P. Vardi, and S. Israel. 2001. Immunogenetics of HLA class II in Israeli Ashkenazi Jewish, Israeli non-Ashkenazi Jewish, and in Israeli Arab IDDM patients. Hum. Immunol.62:85-91.
    OpenUrlCrossRefPubMed
  16. 16.↵
    Motala, A. A., M. Busson, E. M. Al-Harbi, M. A. Khuzam, E. M. Al-Omari, M. R. Arekat, and W. Y. Almawi. 2005. Susceptible and protective human leukocyte antigen class II alleles and haplotypes in Bahraini type 2 (non-insulin-dependent) diabetes mellitus patients. Clin. Diagn. Lab. Immunol.12:213-217.
    OpenUrlPubMed
  17. 17.↵
    Perez-Luque, E., C. Alaez, J. M. Malacara, M. E. Garay, M. E. Fajardo, L. E. Nava, and C. Gorodezky. 2003. Protective effect of DRB1 locus against type 2 diabetes mellitus in Mexican Mestizos. Hum. Immunol.64:110-118.
    OpenUrlCrossRefPubMed
  18. 18.↵
    Valdes, A. M., S. McWeeney, and G. Thomson. 1997. HLA class II DR-DQ amino acids and insulin-dependent diabetes mellitus: application of the haplotype method. Am. J. Hum. Genet.60:717-728.
    OpenUrlPubMedWeb of Science
  19. 19.↵
    Wolford, J. K., and B. Vozarova de Courten. 2004. Genetic basis of type 2 diabetes mellitus: implications for therapy. Treat. Endocrinol.3:257-267.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Zavala, A. V., L. E. Fabiano de Bruno, A. I. Cardoso, A. H. Mota, M. Capucchio, E. Poskus, L. Fainboim, and J. C. Basabe. 1992. Cellular and humoural autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure. Diabetologia35:1159-1164.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
Association of Selective HLA Class II Susceptibility-Conferring and Protective Haplotypes with Type 2 Diabetes in Patients from Bahrain and Lebanon
Wassim Y. Almawi, Saria F. Wakim-Ghorayeb, Mona R. Arekat, Pierre Najm, Sose H. Keleshian, Nasreen Al-Sayed, Bruno Blanchon, Hanady R. Samaha, Noha Irani-Hakime
Clinical and Vaccine Immunology Nov 2006, 13 (11) 1296-1298; DOI: 10.1128/CVI.00206-06

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Association of Selective HLA Class II Susceptibility-Conferring and Protective Haplotypes with Type 2 Diabetes in Patients from Bahrain and Lebanon
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Association of Selective HLA Class II Susceptibility-Conferring and Protective Haplotypes with Type 2 Diabetes in Patients from Bahrain and Lebanon
Wassim Y. Almawi, Saria F. Wakim-Ghorayeb, Mona R. Arekat, Pierre Najm, Sose H. Keleshian, Nasreen Al-Sayed, Bruno Blanchon, Hanady R. Samaha, Noha Irani-Hakime
Clinical and Vaccine Immunology Nov 2006, 13 (11) 1296-1298; DOI: 10.1128/CVI.00206-06
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Diabetes Mellitus, Type 2
Genetic Predisposition to Disease
HLA-DQ Antigens
HLA-DR Antigens
Haplotypes

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X